At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 107 enrolled
Drug / intervention
Raltegravir +1 moredrug
Likely dose
Raltegravir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-naïve Patients With HIV-1 Infection
In Brief
A Phase 4 clinical trial evaluating Raltegravir and Efavirenz for HIV-1 Infection. Completed, enrolled 107 participants across 1 site.
Detailed Summary
A pilot study to compare the efficacy and safety of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesTaiwan
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedNov 2013
Primary CompletionDec 2015
Study CompletionDec 2017
TodayJul 2026
First PostedNov 21, 2013
Enrollment StartSep 1, 2013
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.6 years ago
Interventions
Raltegravirdrug
Raltegravir 400mg oral twice daily
Efavirenzdrug
Efavirenz 600mg oral at bedtime